<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30277">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121717</url>
  </required_header>
  <id_info>
    <org_study_id>CGZ301</org_study_id>
    <nct_id>NCT02121717</nct_id>
  </id_info>
  <brief_title>Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients</brief_title>
  <acronym>CMAP</acronym>
  <official_title>Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chipscreen Biosciences, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chipscreen Biosciences, Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare
      with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy and safety will be compared between Chiglitazar and placebo after treatment of
      24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in HbA1c from baseline after 24 weeks of treatment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline for patients with a baseline HbA1c &gt;=8.5%</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline in patients with a baseline HbA1c &lt; 8.5%</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that attained target HbA1c &lt;7.0%</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients whose HbA1c lowered by at least 0.5%</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose from baseline</measure>
    <time_frame>12,24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-h postprandial glucose (2hPPG) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol (TC) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride from baseline</measure>
    <time_frame>12,24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high density lipoprotein cholesterol (HDL-C)from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in low density proprotein cholesterol (LDL-C) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in free fatty acid (FFA) from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma insulin from baseline</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>12, 24 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who use rescue therapy</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">534</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients administrate Chiglitazar 32mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients administrate Chiglitazar 48mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chiglitazar</intervention_name>
    <description>Take orally</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>CS038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take orally</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Plb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);

          2. HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises;

          3. Male and female,age between 18 and 70 years;

          4. BMI between 18.5-35kg/m2;

          5. Willing to be assigned to any treatment arm and sign inform consent.

        Exclusion Criteria:

          1. Type 1 diabetes;

          2. Treated by oral or injective antidiabetic drug before screening, including insulin
             and herb;

          3. Fasting plasma glucose &gt; 13.3 mmol/L (240 mg/dL);

          4. Resistant hypertension [blood pressure above the goal despite adherence to at least 3
             optimally dosed antihypertensive medications (including diuretic) of different
             classes,or blood pressure is controlled to below the goal by at least 4 different
             classes of drugs];

          5. Plasma triglyceride &gt; 500 mg/dL (5.65 mmol/L);

          6. Is treating by fibrates;

          7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic
             acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic
             nephropathy and diabetic neuropathy;

          8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past
             6 months;

          9. History of myocardial infarction or had conducted coronary angioplasty or coronary
             artery bypass graft surgery;

         10. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy
             indicated by ECG;

         11. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase
             or alanine aminotransferase &gt; 2.5 fold of the upper limit of the normal range;

         12. Kidney diseases or serum creatinine exceed the normal range: male &gt; 133 μmol/L or
             female &gt;108 μmol/L;

         13. Had malignancy in the past 5 years, not including basal cell carcinoma;

         14. Had or is currently receiving treatment that can alter blood glucose metabolism,
             including but not limited to diuretic,hormone (corticotropin or steroids),beta
             blockers;

         15. Have the diseases that can alter blood glucose metabolism, including but not limited
             to active hepatitis, hyperthyroidism,or adrenal tumors;

         16. Edema with unknown reason;

         17. Alcohol or drug addiction;

         18. Had participated other drugs' clinical trials in the 3 months before screening;

         19. Pregnant or lactic women; or women of childbearing age who are not able to or is not
             willing to conduct contraception;

         20. Any condition that make investigator consider the subject is not suitable to
             participate the trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linong Ji, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qian Zhang</last_name>
    <email>zhangqian@chipscreen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Linong Ji, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 306th Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100101</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yanjun Liu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Xin Gao, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chiglitazar,diabetes,type 2 diabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
